[Is systematic use of drug-eluting stents justified? Arguments in favour]

The efficacy of drug-eluting stents measured as the late loss, percentage neointimal volume, restenosis, target lesion revascularization and major cardiac events is significantly better than that of bare metal stents. The incidence of thrombosis and aneurysms is similar. Although there is a slight increase in late apposition, this is not followed by an increase in cardiac events. Despite the arguments against the routine use of drug-eluting stents, their cost is the only limiting factor for their widespread use.